Literature DB >> 17991347

Probiotics in the management of colonic disorders.

Eamonn M M Quigley1.   

Abstract

Probiotics have been used in humans for almost a century and widely recommended for the treatment of a variety of ills assumed to be of colonic origin, including diarrhea, constipation, bloating, and flatulence. More recently, probiotics have been evaluated in the management of specific colonic disorders such as inflammatory bowel disease, irritable bowel syndrome, and Clostridium difficile colitis. It is evident that no two probiotics are exactly alike; why then should we expect reproducible results from studies that employ different species or strains, variable formulations, and diverse dosing schedules? When probiotics have been studied with the rigor appropriate to a new therapeutic modality, some coherent results have emerged: specific strains are effective in certain diarrheal states, irritable bowel syndrome, ulcerative colitis, and pouchitis, as well as in the prevention of C. difficile-related colitis. Even here, not to mention other colonic disorders, further adequately powered and appropriately designed trials are needed.

Entities:  

Mesh:

Year:  2007        PMID: 17991347     DOI: 10.1007/s11894-007-0055-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  67 in total

Review 1.  Probiotic effects on inflammatory bowel disease.

Authors:  Barbara Sheil; Fergus Shanahan; Liam O'Mahony
Journal:  J Nutr       Date:  2007-03       Impact factor: 4.798

2.  Use of probiotics for prevention of radiation-induced diarrhea.

Authors:  P Delia; G Sansotta; V Donato; P Frosina; G Messina; C De Renzis; G Famularo
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 3.  Probiotics for maintenance of remission in Crohn's disease.

Authors:  V E Rolfe; P J Fortun; C J Hawkey; F Bath-Hextall
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 4.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

Authors:  E M M Quigley; B Flourie
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

5.  Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children.

Authors:  H Szajewska; A Skórka; M Dylag
Journal:  Aliment Pharmacol Ther       Date:  2007-02-01       Impact factor: 8.171

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis.

Authors:  A-P Bai; Q Ouyang; X-R Xiao; S-F Li
Journal:  Int J Clin Pract       Date:  2006-03       Impact factor: 2.503

Review 8.  Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.

Authors:  Aloysius L D'Souza; Chakravarthi Rajkumar; Jonathan Cooke; Christopher J Bulpitt
Journal:  BMJ       Date:  2002-06-08

9.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

10.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  7 in total

Review 1.  Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease.

Authors:  Antonio Tursi; Raymond E Joseph; Paul Streck
Journal:  Dig Dis Sci       Date:  2011-05-13       Impact factor: 3.199

2.  Diverticular disease: A therapeutic overview.

Authors:  Antonio Tursi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

3.  Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

4.  Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).

Authors:  Harald Matthes; Thomas Krummenerl; Manfred Giensch; Corinna Wolff; Jürgen Schulze
Journal:  BMC Complement Altern Med       Date:  2010-04-15       Impact factor: 3.659

5.  Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.

Authors:  Andrea M Stringer; Rachel J Gibson; Joanne M Bowen; Richard M Logan; Kimberly Ashton; Ann S J Yeoh; Noor Al-Dasooqi; Dorothy M K Keefe
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

6.  New strategies for the management of diverticular disease: insights for the clinician.

Authors:  Wen Boynton; Martin Floch
Journal:  Therap Adv Gastroenterol       Date:  2013-05       Impact factor: 4.409

7.  Quantitative real time PCR detection of Clostridium difficile growth inhibition by probiotic organisms.

Authors:  Bryan L Folkers; Craig Schuring; Michael Essmann; Bryan Larsen
Journal:  N Am J Med Sci       Date:  2010-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.